Kaisa Health Group Holdings Limited Overview
Qinghai Biotech Pharmaceutical Group is a Hong Kong-listed, Bermuda-incorporated micro-cap healthcare holding company controlled by distressed property developer Kaisa Group. Its legacy business is mid-to-high-end dental prosthetics and implants under the "Mega" and "Basic" brands, sold mainly in mainland China, with production in Shanghai, Chengdu and the United States. It also runs a small sports-rehabilitation clinic in Shenzhen ("Hejia"). In June 2026 it absorbed a controlling 54.84% stake in Qinghai Pharmaceutical, a state-designated manufacturer of anaesthetic, narcotic and psychotropic active pharmaceutical ingredients (APIs) and finished drugs. That business now generates about 77% of group revenue. The rebranded group says it is building a three-pillar "pharmaceuticals + dental devices + rehabilitation services" ecosystem. The scarce narcotics licences are a genuine strategic asset. They sit alongside a highly leveraged acquired balance sheet carrying bank debt, a RMB600 million-capped third-party financial guarantee linked to Kaisa affiliates, a deficit in shareholders' equity and a disclosed material going-concern uncertainty.
Company's own description (latest filings)
In its FY2025 annual results announcement, the company describes itself as an investment holding company whose group is mainly engaged in manufacturing and selling dental prosthetics and implant instruments and providing sport rehabilitation services.
The 2026 interim results (25 August 2026) describe three core segments:
-
pharmaceutical manufacturing;
-
research, production and sale of dental consumables;
-
sports rehabilitation medical services.
Management says the June 2026 restructuring "formally" established a synergistic layout across these three health industries. The stated aim is to become a listed enterprise providing distinctive and comprehensive medical healthcare services in China, with Qinghai Pharmaceutical as the "core brand" and "Mega" and "Hejia Clinic" as complements.
Independent characterisation
Economically, the group is now a specialty pharmaceutical manufacturer with a sub-scale dental devices business and a negligible clinic business attached.
- Pharmaceutical Business (Qinghai Pharmaceutical, 54.84% owned). It manufactures anaesthetic and antitussive APIs and finished products, including narcotic and Class I psychotropic drugs, under China's tightly controlled licensing system. The revenue model is product sales (point-in-time recognition) to hospitals, pharmacy chains and pharmaceutical distributors nationwide. One distributor ("Customer A") accounted for HK$61.8 million, or 21.7% of group revenue, in H1 2026.
Dental Business: It manufactures and sells dental prosthetics (crowns and bridges, removable full and partial dentures, implants, full-cast restorations), digital aesthetic products (veneers, 3D simulated zirconia, clear aligners) and dental implants. Customers are dentists, dental laboratories and technicians, public hospitals (via tenders) and private dental chains in China and overseas. Revenue is 100% product sales, recognised at a point in time. The business has been hurt badly by China's volume-based or centralised procurement (VBP) price ceilings for dental implants and consumables.
Health Care Business (Hejia Rehabilitation): A single Shenzhen clinic offers post-operative and sports-injury rehabilitation, chronic pain treatment, scoliosis and deformity correction. It is a Shenzhen medical-insurance designated provider. Revenue is service fees, with some prepayment packages booked as contract liabilities.
Financial investments: The group holds limited-partnership interests carried at fair value through profit or loss (FVTPL):
-
Zhuhai Jinyiming Equity Investment Fund, 5.51%, cost RMB180 million, held via a VIE structure;
-
Haoyi Healthcare Services Partnership, 99.9% LP interest, holding the Zhuhai Shili Lianjiang health-leisure/tourism project. Together these were worth HK$151.2 million at 30 June 2026. Before the merger they were the single largest asset class, at 34.4% of total assets at end-2025.
Revenue model mix
| Revenue type | H1 2026 (HKD Mn) | Share of revenue |
|---|---|---|
| Product sales: pharmaceuticals | 219.9 | 77.3% |
| Product sales: dental prosthetics and implant instruments | 60.5 | 21.3% |
| Services: rehabilitation and health leisure | 4.2 | 1.5% |
| Subscription / licensing | 0 | 0% |
| Total | 284.6 | 100% |
Source: 2026 Interim Results Announcement, Note 4.
Value-chain position
Pharmaceuticals: vertically integrated from API synthesis to finished dosage forms, with its own nationwide distribution relationships. It sits upstream of hospitals and distributors in a licensed oligopoly for controlled substances.
Dental: a mid-stream manufacturer and lab-style producer of custom prosthetics and implant systems. It sells to dental clinics and chains, competes in public-hospital tenders, and depends on dentist and technician relationships.
Rehabilitation: a downstream direct-to-patient service provider.
End-markets served
-
China hospital anaesthesia and analgesia (surgical anaesthesia, critical and emergency care, pain management) and antitussives.
-
China dental restoration, aesthetic dentistry and implantology, plus export prosthetics, chiefly to the US.
-
China (Shenzhen) sports-medicine and rehabilitation services.
Strategy
Stated strategy themes (2026 Interim Results, Prospects)
Group vision: an "integrated health industry ecosystem" across APIs and finished drugs, high-end dental devices and professional sports rehabilitation. Qinghai Pharmaceutical is the core brand; "Mega" and "Hejia Clinic" are complements. The aim is a "closed-loop" competitive barrier of "medical devices + pharmaceuticals + medical services".
FY2025 framing (pre-merger): become the industry leader in high-end dental consumables and regional sports rehabilitation, with "Mega" and "Basic" as core brands.
Pharmaceutical — five strategic directions (2026 Interim)
-
Deepen integration. Merge Qinghai's middle and back office with HQ; centralise procurement, sales and financing; revitalise idle assets.
-
R&D and production. Launch hydromorphone hydrochloride and expand capacity; revive the pipeline; advance clinical trials and registrations; upgrade the quality system.
-
Distribution. Widen coverage of public hospitals, pharmacy chains and distributors.
-
Capital markets. Use the HK listing for placements, industrial bonds and strategic investors; pursue specialised API and product M&A at home and abroad.
-
Cross-segment synergy. Link in-house drugs with post-dental-surgery care and sports-injury rehabilitation.
Dental — four priorities
-
Upgrade automated lines in Chengdu, Shanghai and the US; scale implant and digital denture output.
-
Expand channels: trade shows, public-hospital tenders, chain partnerships with on-site technician services, overseas distribution.
-
R&D: clear aligners, ultra-thin veneers, next-generation implant materials.
-
Pursue M&A in high-tech dental niches.
Health Care — four priorities (H2 2026)
-
Build the regional brand in Shenzhen, including Peking University Shenzhen Hospital collaboration.
-
Diversify payment through commercial-insurance direct billing.
-
Expand the clinical team and standardise care.
-
Strengthen medical-insurance compliance.
Initiatives in the last 24 months
| Initiative | Date | Status |
|---|---|---|
| Basic (Chengdu) implant plant licensing and ramp-up | Jun 2024 – Sep 2025 | Producing |
| Sino-US Implant R&D Centre team expansion | 2024–2026 | Ongoing |
| Acquisition of Qinghai Pharmaceutical (54.84%) | Mar–Jun 2026 | Completed |
| 50:1 share consolidation | Jun 2026 | Completed |
| 2026 Share Scheme | Jun 2026 | Adopted; no grants |
| Rebrand to Qinghai Biotech Pharmaceutical Group | Jul–Sep 2026 | Appears effective per market data |
| Hydromorphone hydrochloride registration and production line | Jul 2026 onward | Line under construction |
| Commercial-insurance partnerships (Hejia) | 2025–2026 | Ongoing |
Cost programmes: none with quantified targets. FY2025 administrative costs fell 23.7% on lower labour costs.
ESG commitments: none quantified in sources reviewed.
Medium-term financial targets / guidance: none published.
Products & Services
Pharmaceutical Business (Qinghai Pharmaceutical)
| Product / line | Description | Target customer | Launch / status | Pricing |
|---|---|---|---|---|
| Anaesthetic APIs | Active pharmaceutical ingredients for anaesthetic and narcotic drugs, produced under state-designated controlled-substance licences | Formulation manufacturers; internal use | Established; specific molecules not itemised in filings | Not publicly disclosed; subject to state price controls for narcotics |
| Narcotic and Class I psychotropic finished preparations | Finished dosage forms for surgical analgesia and critical or emergency care (per market commentary) | Hospitals (via distributors) | Established | — |
| Antitussive products | Cough-suppressant APIs and products (the filings name "anaesthetic antitussive" as a principal category) | Hospitals, pharmacy chains, distributors | Established | — |
| Chemical preparations | General chemical drug formulations (per market commentary) | Hospitals, pharmacies | Established | — |
| Hydromorphone hydrochloride | Opioid analgesic; drug registration certificate granted July 2026; production line under construction | Hospitals (pain management) | Registered Jul 2026; not yet in commercial production | — |
| Portfolio breadth | 124 products across 156 specifications, 21 exclusive varieties (Tiger Brokers; Mar 2026) | — | — | — |
Dental Business
| Product / brand | Description | Target customer | Launch / latest | Pricing |
|---|---|---|---|---|
| Crowns and bridges | Fixed prosthetics, including porcelain-fused-to-metal and all-ceramic | Dentists, labs, domestic and export | Long-established | Per unit; VBP price ceilings in China |
| Removable full and partial dentures | Removable prosthetics | Dentists; export | Long-established | Per case |
| Full-cast restorations | Metal cast restorations | Dentists | Long-established | Per case |
| Dental implants ("Basic" brand) | Implant systems produced at Basic (Chengdu) plant, Sino-US Implant R&D Centre and US base; NMPA approved more sizes Jul 2024 | Public hospitals (tender), dental chains (Shandong, Shanghai) | Chengdu plant producing since late 2025 | Subject to national implant VBP pricing |
| Implant instruments | Surgical and prosthetic components for implant procedures | Dentists | Ongoing | — |
| Mega Veneer XS (美加貼面XS) | Ultra-thin, minimally invasive aesthetic veneer | Aesthetic dentistry clinics | Launched 2019 under "Mega" | — |
| Mega 3D Simulation Zirconium (美加3D模擬鋯) | Digitally designed, 3D-printed or milled zirconia restoration | Dentists, labs | Launched 2019 | — |
| Mega YiQi Clear Aligner (美加易齊透明矯正器) | Invisible orthodontic aligner, supported by in-house orthodontic software under development | Orthodontists, general dentists | Launched 2019; iteration ongoing | — |
| Removable prosthetic devices (Mega) | Digital removable prostheses | Dentists | Launched 2019 | — |
| Teeth whitening / cosmetic dentistry offering | Part of the "one-stop" aesthetic restoration solution | Clinics | Ongoing | — |
| Digital workflow R&D (in progress) | 3D engraving machines, 3D printers, 3D scanners, invisible orthodontic software | Internal / future products | R&D stage (FY2025) | — |
Health Care Business
| Service | Description | Target customer | Status | Pricing |
|---|---|---|---|---|
| Post-operative rehabilitation | Rehabilitation after orthopaedic and sports surgery | Patients (Shenzhen) | Ongoing | Fee per session or package; medical insurance and commercial insurance accepted |
| Sports-injury rehabilitation | Specialist sports medicine rehab | Athletes, active population | Ongoing | As above |
| Chronic pain management | Non-surgical pain therapy | General patients | Ongoing | As above |
| Scoliosis and deformity correction | Corrective therapy programmes | Adolescents and adults | Ongoing | As above |
| Health leisure (via Haoyi / Shili Lianjiang) | Light tourism health-leisure project in Zhuhai; now a passive FVTPL investment | Consumers | Deconsolidated June 2023 | — |
Credentials (Hejia).
-
Shenzhen medical-insurance designated institution; passed its periodic evaluation in H1 2026.
-
Council member of the China Sports Rehabilitation Industry Alliance.
-
Founding committee member of the Sports and Health Branch of the Shenzhen Preventive Medicine Association (2025).
-
Long-term academic and clinical collaboration with Peking University Shenzhen Hospital.
Financial Narrative
Basis. FY2021–FY2025 figures are as originally reported, before the merger restatement. FY2024–FY2025 come from the FY2025 Results Announcement. FY2021–FY2023 come from S&P Global Market Intelligence via StockAnalysis, cross-checked to the 2022 and 2023 Annual Reports for revenue: HK$191.5 million in FY2022 and HK$185.9 million in FY2023, which match.
Income statement
Pre-tax income for FY2021–FY2023 is derived from S&P pre-tax margins (5.34%, -89.28%, 3.25%). Post-consolidation EPS is from S&P and reflects the 50:1 consolidation.
FY2025 detail (HK$ '000):
-
Revenue 139,112; cost of sales (88,468); gross profit 50,644.
-
Other income 1,583; selling and distribution (51,182); administrative (35,086); R&D (16,911).
-
FVTPL gain 10,562; trade receivable impairment (2,860); other receivable impairment (3,103); finance costs (592).
-
Loss before tax (46,945); tax credit 97; loss for the year (46,848), of which owners (46,678).
Revenue CAGR FY2021–FY2025: -9.7% per year (HK$209.6 million to HK$139.1 million).
Commentary.
Revenue: Revenue was flat at about HK$185–192 million from FY2022 to FY2024, then fell 25% in FY2025. The FY2025 drop was almost entirely dental (-HK$47.0 million). The company attributes it to lower selling prices under China's centralised procurement policy.
Gross margin: Gross margin held at 43–46% through FY2024, then compressed to 36.4% in FY2025.
Operating losses: The group has run structural operating losses every year. Selling costs (HK$51.2 million in FY2025, about 37% of revenue) and administrative costs consume all gross profit.
Net income: Positive net income in FY2021 and FY2023 came from non-operating items. Neither year reflects operating profitability.
FY2022: The FY2022 loss of about HK$123 million was the largest in the period.
FY2025 swing factors: Administrative costs fell 23.7% (lower labour costs) and other-receivable impairment fell from HK$21.9 million to HK$3.1 million. These offset the gross-profit collapse, so the headline loss was little changed at HK$46.7 million.
Restated (post-merger) interim income statement
Source: 2026 Interim Results, Note 2.4 and income statement.
Data quality flag: H1 2026 LPS of 1.24 HK cents is computed on 4,850,086 thousand weighted shares, while H1 2025 restated (7.67 cents) uses 100,842 thousand post-consolidation shares. The H1 2026 denominator appears inconsistent with the 103.6 million post-consolidation share count. On a post-consolidation basis, H1 2026 LPS would be about HK$0.58 per share. Treat the reported 1.24 cents with caution.
Balance sheet: notes and sources
Sources: FY2025 Results (FY2024–FY2025); S&P Global via StockAnalysis (FY2021–FY2023). Bank borrowings were nil before the merger; debt consisted of lease liabilities only.
Restated balance sheet
Source: 2026 Interim Results. The 1 January 2025 total assets figure is the sum of disclosed non-current and current assets.
Restated ratios (30 June 2026):
-
Current ratio 0.46; quick ratio 0.32.
-
Gearing, as defined by the company (net debt including guarantee and litigation provisions ÷ (net debt + total equity)), about 1.13.
-
Company-defined target-group net debt about HK$1,052.2 million.
Cash flow
Source: S&P Global via StockAnalysis. The company's own disclosure of capital expenditure including right-of-use assets is HK$7.4 million (FY2024) and HK$21.2 million (FY2025). The differences reflect lease additions.
Commentary. The legacy group has burned cash every year: cumulative free cash flow of about -HK$351 million over FY2021–FY2025. Cash fell from HK$259 million to HK$110 million. On the restated basis, cash fell to HK$33.4 million by June 2026, mainly because about HK$115.5 million was used to settle the Ruihong litigation provision.
Ratios
Notes:
-
Ratios are computed by the analyst from the tables above.
-
ROIC, net debt/EBITDA and interest coverage are not meaningful: EBIT and EBITDA are negative and the legacy group had net cash.
-
CCC FY2025 is DSO 246 days + DIO 60 days − DPO 25 days.
-
Restated, post-merger figures from S&P (trailing twelve months to June 2026): ROE -71.8%; ROA -4.8%; ROIC -18.0%; Altman Z-score -0.91; Piotroski F-score 2. These blend restated and unrestated periods and should be used with caution.
Ratio commentary.
Receivables: The cash conversion cycle lengthened sharply because receivables ballooned relative to sales. Trade receivables over 1 year old tripled from HK$6.8 million to HK$17.4 million. Those aged 181–365 days rose from HK$20.0 million to HK$25.4 million. Some well-established customers have 360-day terms.
Liquidity: The legacy current ratio looked strong (3.98) because cash was large relative to small payables. The post-merger current ratio of 0.46 is the relevant one going forward.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services | Status |
|---|---|---|---|
Pharmaceutical Business | Qinghai Pharmaceutical Co., Ltd. and subsidiaries (the "Project Group"). Held 54.84% via Embrace Blossom → Sino Globe (HK) → Chenghe Industrial Development (Dongguan) (99%) → Kaisa Healthcare Investment (Shenzhen) (100%). | R&D, manufacture and sale of anaesthetic and psychotropic APIs and finished products, and antitussives; hydromorphone hydrochloride registered July 2026 | New from H1 2026. Prior periods restated under merger accounting. |
Dental Business | Manufacturing of, and trading in, dental products | Crowns and bridges, removable full and partial dentures, implants, full-cast restorations, veneers, 3D simulated zirconia, clear aligners, implant instruments | Legacy core |
Health Care Business | Hejia Rehabilitation Clinic (Shenzhen); FVTPL investments in the Zhuhai and Haoyi partnerships are allocated here | Post-operative and sports-injury rehabilitation, chronic pain, scoliosis and deformity correction; health leisure | Legacy, sub-scale |
Segment revenue (HKD Mn)
| Segment revenue (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dental Business revenue (HKD Mn) | 200.49 | 181.28 | 179.44 | 178.98 | 132.03 |
Health Care Business revenue (HKD Mn) | — | 10.22 | 6.44 | 6.38 | 7.08 |
Total revenue (HKD Mn) | 209.63 | 191.50 | 185.88 | 185.36 | 139.11 |
Revenue by Segment (%) and Segment Margins & Growth (%)
| Segment metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dental share of revenue (%) | 95.6 | 94.7 | 96.5 | 96.6 | 94.9 |
Health Care share of revenue (%) | — | 5.3 | 3.5 | 3.4 | 5.1 |
Dental revenue YoY growth (%) | — | -9.6 | -1.0 | -0.3 | -26.2 |
Health Care revenue YoY growth (%) | — | — | -37.0 | -0.9 | 11.0 |
Segment Margins & Growth (%)
| Line item | Dental FY2024 | Health Care FY2024 | Dental FY2025 | Health Care FY2025 |
|---|---|---|---|---|
External revenue | 178,981 | 6,376 | 132,034 | 7,078 |
Segment profit/(loss) before D&A | 19,306 | 524 | (31,956) | 509 |
Depreciation: PP&E | (5,759) | (1,909) | (5,642) | (1,089) |
Depreciation: right-of-use assets | (4,361) | (2,478) | (3,706) | (1,790) |
Amortisation of intangibles | (354) | (313) | (354) | (412) |
Segment profit/(loss) before tax, before impairments and FV | 8,832 | (4,176) | (41,658) | (2,782) |
Impairment / reversal on trade receivables | 983 | — | (2,860) | — |
FV gain/(loss) on FVTPL | — | (9,772) | — | 10,562 |
Segment profit/(loss) before tax | 9,815 | (13,948) | (44,518) | 7,780 |
Operating margin before impairments and FV (%) | 4.9 | -65.5 | -31.6 | -39.3 |
Segment assets (year end) | 304,044 | 211,758 | 291,887 | 178,288 |
Capex | 6,943 | 495 | 18,008 | 3,173 |
Segment Revenue
| Line item | Dental H1'25 | Health Care H1'25 | Pharma H1'25 | Dental H1'26 | Health Care H1'26 | Pharma H1'26 |
|---|---|---|---|---|---|---|
External revenue | 66,433 | 3,144 | 268,622 | 60,526 | 4,210 | 219,853 |
Segment profit/(loss) before D&A | (12,030) | 2,538 | 38,709 | (16,690) | (2,014) | (766) |
Depreciation and amortisation (total) | (4,628) | (1,781) | (19,974) | (4,587) | (1,609) | (21,710) |
Segment profit/(loss) before tax, before impairments and FV | (16,658) | 757 | 18,735 | (21,277) | (3,623) | (22,476) |
Trade receivable impairment / reversal | 197 | — | (6,542) | 3,122 | — | (3,494) |
Financial guarantee impairment | — | — | — | — | — | (134) |
FVTPL gain/(loss) | — | 8,979 | — | — | (14,946) | — |
Segment profit/(loss) before tax | (16,461) | 9,736 | 12,193 | (18,155) | (18,569) | (26,104) |
H1 segment revenue (HKD Mn)
| H1 segment revenue (HKD Mn) | H1 2025 restated | H1 2026 |
|---|---|---|
Pharmaceutical Business revenue (HKD Mn) | 268.62 | 219.85 |
Dental Business revenue (HKD Mn) | 66.43 | 60.53 |
Health Care Business revenue (HKD Mn) | 3.14 | 4.21 |
Total revenue (HKD Mn) | 338.20 | 284.59 |
Segment Overview — Dental
| Segment | Assets | Liabilities |
|---|---|---|
Dental | 274,052 | (73,885) |
Health Care | 96,330 | (12,028) |
Pharmaceutical | 1,343,127 | (1,717,270) |
Group total (including unallocated) | 1,721,418 | (1,840,238) |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 209.63 | 191.50 | 185.88 | 185.36 | 139.11 |
Revenue growth YoY (%) | 14.04 | -8.65 | -2.93 | -0.28 | -24.95 |
Gross profit (HKD Mn) | 97.42 | 82.57 | 81.07 | 81.86 | 50.64 |
Operating income, S&P definition (HKD Mn) | -77.93 | -72.24 | -43.74 | -23.23 | -55.40 |
EBITDA, derived as LBT + finance costs + D&A (HKD Mn) | — | — | — | -32.73 | -33.36 |
Pre-tax income (HKD Mn) | 11.19 | -170.97 | 6.04 | -48.68 | -46.95 |
Net income attributable to owners (HKD Mn) | 2.36 | -123.32 | 7.47 | -46.36 | -46.68 |
EPS basic and diluted, post-consolidation basis (HKD) | 0.02 | -1.22 | 0.07 | -0.46 | -0.46 |
EPS basic, as reported pre-consolidation (HK cents) | — | — | — | -0.92 | -0.93 |
Dividends per share (HKD) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin
| Margin | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 46.47 | 43.11 | 43.61 | 44.16 | 36.41 |
Operating margin (%) | -37.17 | -37.72 | -23.53 | -12.53 | -39.82 |
EBITDA margin (%) | — | — | — | -17.66 | -23.98 |
Pre-tax margin (%) | 5.34 | -89.28 | 3.25 | -26.26 | -33.75 |
Net margin, attributable (%) | 1.13 | -64.40 | 4.02 | -25.01 | -33.55 |
Margin Analysis (%)
| Line item | H1 2025 as previously reported | H1 2025 restated | H1 2026 |
|---|---|---|---|
Revenue | 69,577 | 338,199 | 284,589 |
Gross profit | 25,194 | 140,302 | 107,834 |
Gross margin (%) | 36.2 | 41.5 | 37.9 |
Selling and distribution | (21,760) | (62,285) | (56,173) |
Administrative | (14,729) | (49,353) | (54,659) |
R&D | (7,779) | (22,087) | (27,424) |
FVTPL gain/(loss) | 8,979 | 8,979 | (14,946) |
Finance costs | (228) | (20,020) | (11,160) |
Profit/(loss) before tax | (9,334) | 2,863 | (67,183) |
Profit/(loss) for period | (9,285) | 2,708 | (62,477) |
Attributable to owners | (9,125) | (7,739) | (60,168) |
Attributable to NCI | (160) | 10,447 | (2,309) |
LPS (HK cents, post-consolidation for restated) | (0.18) | (7.67) | (1.24) |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 971.33 | 767.60 | 605.07 | 517.59 | 471.71 |
Cash and equivalents (HKD Mn) | 259.26 | 173.45 | 174.08 | 149.61 | 109.60 |
Short-term debt, current lease liabilities (HKD Mn) | 6.75 | 7.01 | 7.82 | 4.21 | 5.39 |
Long-term debt, non-current lease liabilities (HKD Mn) | 25.53 | 24.86 | 10.18 | 6.44 | 8.08 |
Total debt (HKD Mn) | 32.28 | 31.87 | 18.00 | 10.65 | 13.46 |
Net debt, negative = net cash (HKD Mn) | -226.98 | -141.58 | -156.08 | -138.96 | -96.14 |
Total equity (HKD Mn) | 682.84 | 470.91 | 491.76 | 426.49 | 398.50 |
Equity attributable to owners (HKD Mn) | 651.12 | 485.33 | 492.01 | 431.15 | 403.38 |
Goodwill (HKD Mn) | 20.22 | 20.22 | 20.22 | 20.22 | 20.22 |
Other intangible assets (HKD Mn) | 9.31 | 8.32 | 3.74 | 3.07 | 4.15 |
FVTPL partnership investments (HKD Mn) | 230.34 | 200.28 | 193.11 | 160.26 | 162.24 |
Working capital (HKD Mn) | 313.84 | 205.12 | 253.03 | 228.02 | 192.54 |
Financial Analysis
| Line item | 1 Jan 2025 restated | 31 Dec 2025 restated | 30 Jun 2026 |
|---|---|---|---|
Property, plant and equipment | 268,364 | 294,031 | 302,855 |
Intangible assets | 135,388 | 111,141 | 98,033 |
Goodwill | 522,553 | 548,283 | 567,475 |
FVTPL | 160,261 | 162,237 | 151,184 |
Inventories | 242,248 | 191,222 | 175,632 |
Trade and other receivables | 208,076 | 285,201 | 353,374 |
Bank balances and cash | 316,865 | 137,894 | 33,370 |
Total assets | 1,881,155 | 1,771,772 | 1,721,418 |
Provision for financial guarantee | — | 661,449 | 685,623 |
Provision for litigations | 147,875 | 146,425 | — |
Bank borrowings, current | 446,620 | 55,720 | 75,069 |
Bank borrowings, non-current | — | 335,769 | 324,873 |
Amounts due to fellow subsidiaries | 191,330 | 201,163 | 231,613 |
Net current liabilities | (310,863) | (645,253) | (669,071) |
Net assets / (liabilities) | 627,705 | (95,431) | (118,820) |
Equity / (deficit) attributable to owners | 394,147 | (294,497) | (322,782) |
Non-controlling interests | 233,558 | 199,066 | 203,962 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | -122.81 | -58.58 | -35.82 | -34.05 | -47.32 |
Capital expenditure (HKD Mn) | -13.79 | -13.38 | -10.88 | -5.00 | -9.33 |
Free cash flow (HKD Mn) | -136.60 | -71.96 | -46.70 | -39.05 | -56.65 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable net income ÷ average owners' equity (%) | — | -21.70 | 1.53 | -10.04 | -11.19 |
ROA, attributable net income ÷ average total assets (%) | — | -14.18 | 1.09 | -8.26 | -9.44 |
Current ratio (x) | 2.20 | 1.76 | 3.47 | 3.71 | 3.98 |
Debt to equity (x) | 0.05 | 0.07 | 0.04 | 0.02 | 0.03 |
Asset turnover (x) | — | 0.22 | 0.27 | 0.33 | 0.28 |
Cash conversion cycle (days) | — | — | — | 200 | 281 |
Geographic revenue share (%)
| Geographic revenue share (%) | FY2024 | FY2025 |
|---|---|---|
PRC excluding Hong Kong, minimum disclosed (%) | 90 | 90 |
Rest of world, maximum implied (%) | 10 | 10 |
Geographic Revenue
| Region | FY2024 | FY2025 |
|---|---|---|
PRC excluding Hong Kong | 22,679 | 30,122 |
Others (including US, HK) | 22,605 | 22,208 |
Total | 45,284 | 52,330 |
Valuation Snapshot
| Metric | Value |
|---|---|
Last close | HK$1.82 (9 Oct 2026) |
52-week change | -27.2% |
50-day moving average | HK$1.92 |
200-day moving average | HK$4.56 |
Market cap | HK$188.6 million |
Enterprise value | HK$769.7 million |
P/E | n/a (loss-making) |
EV/EBITDA | n/a (negative EBITDA) |
P/S (data provider, mixed-basis TTM) | 2.21x |
EV/Sales (data provider, mixed-basis TTM) | 9.0x |
P/B | Negative (book value -HK$118.8 million) |
Beta (5Y) | 1.10 |
Average volume (20-day) | ≈24,880 shares |
Capital Markets
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (HKD) | 0 | 0 | 0 | 0 | 0 |
Buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Debt Maturity Profile
| Maturity bucket | HKD Mn |
|---|---|
Within 1 year or on demand (bank) | 75.1 |
1–2 years (bank) | 324.9 |
Lease liabilities, total | 10.5 |
Due to fellow subsidiaries (on demand, interest-free) | 231.6 |
Financial guarantee provision (current) | 685.6 |
Analyst Conclusions
Management guidance
No quantitative guidance. Qualitatively, management:
-
expects Qinghai Pharmaceutical to be the "core growth engine";
-
prioritises the hydromorphone launch;
-
will consider equity or bond financing and M&A;
-
will "prudently manage debt levels".
It also asserts the group is "financially strong" with adequate resources. That sits uneasily with its own going-concern disclosure in the same document.
Consensus expectations
None (no coverage).
Bull case
-
Licence value. Narcotic and psychotropic licences are near-irreplaceable; at a market cap of HK$189 million, investors buy majority control of a business that generated HK$268.6 million of revenue in H1 2025 alone.
-
Product catalyst. Hydromorphone commercialisation from 2027 could lift revenue and margins, with the production line already under construction and capex commitments of HK$119.3 million.
-
Balance-sheet clean-up. Litigation was cleared in H1 2026, and the debt maturity runs to December 2028. A placement or strategic investor could recapitalise the equity deficit.
Bear case
-
Imported liabilities. The deal brought in HK$686 million of guarantee provisions and HK$400 million of bank debt. Equity attributable to owners is -HK$323 million, and cash was only HK$33 million at June 2026.
-
Profit deterioration. Pharma revenue fell 18% and swung to a segment loss in its first reported half. Dental revenue is still shrinking under VBP.
-
Governance. Liquidity depends on a distressed parent's support letter. The acquired subsidiary guaranteed a defaulted affiliate loan days before the deal process, and minorities bear the dilution and risk.
Key catalysts and monitorables (next 12 months)
-
Confirmation of the name change and new stock short name; the FY2026 annual results (March 2027) and auditor opinion, including any going-concern emphasis or qualification.
-
Hydromorphone production start and first sales.
-
Any demand under the Shenzhen City Jingjia guarantee, and the Minsheng repayment schedule.
-
Equity placement or strategic investor terms (dilution).
-
Collection of receivables aged 181–365 days (HK$113.6 million).
-
Customer A concentration and any VBP inclusion of anaesthetic products.
-
Kaisa Group restructuring progress, given the support letter runs to June 2027.
-
Dental VBP pricing trends and Basic implant tender wins.
Analyst verdict
Qinghai Biotech Pharmaceutical Group is best understood as a holding vehicle into which a distressed property conglomerate has injected its most valuable healthcare asset, together with that asset's liabilities.
The legacy Kaisa Health business was never self-sustaining:
-
it posted operating losses in every one of the last five years;
-
free cash flow was cumulatively about -HK$351 million;
-
dental revenue fell 26% in FY2025 as centralised procurement compressed prices.
Its main virtue was a clean, net-cash balance sheet, and the June 2026 merger replaced that with a deficit in shareholders' equity.
The strategic logic of owning Qinghai Pharmaceutical is real. China's narcotic and psychotropic drug licences are scarce, the product set serves non-discretionary surgical and critical-care demand, and the new hydromorphone registration is a credible growth lever. The headline consideration of HK$24.4 million is optically modest.
The price paid in balance-sheet risk is not modest:
-
a HK$686 million financial guarantee provision tied to a Kaisa affiliate's defaulted RMB1.6 billion loan;
-
HK$400 million of previously defaulted bank debt secured on the Qinghai shares;
-
HK$232 million owed to fellow subsidiaries.
Against these, cash was HK$33 million in June 2026, and the directors rely on a support letter from a parent with about RMB30.5 billion of borrowings.
First-half 2026 results did not yet show the promised engine. Pharmaceutical revenue fell 18% and the segment moved to a loss after acquisition-related amortisation.
For institutional investors, the equity is effectively a deep-out-of-the-money option on two things: Qinghai Pharmaceutical's earnings recovering, and the guarantee exposure being resolved without crystallising. Liquidity is thin, there is no analyst coverage and disclosure is limited.
We would classify the stock as speculative / high risk. Engagement is justified only for special-situations mandates able to underwrite the guarantee and parent-support risks directly. The decisive monitorables are the FY2026 audit opinion, the hydromorphone launch timetable and any recapitalisation terms.
Sources (primary and secondary)
-
Kaisa Health Group Holdings Ltd, Annual Results Announcement FY2025, HKEXnews, 25 Mar 2026.
-
Kaisa Health Group Holdings Ltd, Interim Results Announcement for six months ended 30 Jun 2026, HKEXnews, 25 Aug 2026.
-
Kaisa Health Group Holdings Ltd, Profit Warning, HKEXnews, 19 Aug 2026.
-
Kaisa Health Group Holdings Ltd, Change of Executive Director, HKEXnews, 13 Jul 2026.
-
Kaisa Health Group Holdings Ltd, Revised Proposal on Change of Company Name (circular), HKEXnews, 13 Aug 2026.
-
Kaisa Health Group Holdings Ltd, 2025 Interim Report (25 Sep 2025) and 2025 Interim Results (27 Aug 2025), HKEXnews.
-
Kaisa Health Group Holdings Ltd, Annual Reports 2022 (28 Apr 2023) and 2023 (29 Apr 2024); Supplemental Announcement to 2023 AR (2 Aug 2024).
-
Mega Medical Technology Ltd announcement (7 Aug 2017); Kaisa Health supplemental announcement on 2017 AR (18 Oct 2018).
-
Kaisa Group Holdings Ltd, FY2025 Annual Results (31 Mar 2026); Kaisa Group announcement on Qinghai Pharmaceutical divestment (18 Mar 2026, via Tiger Brokers).
-
S&P Global Market Intelligence via StockAnalysis.com: HKG:0876 financials, balance sheet and statistics (accessed Oct 2026); HKG:2954 page.
-
etnet company information (board, major shareholders, advisers).
-
Tiger Brokers news (Mar 2026); TipRanks announcement feed (2025); Longbridge news feed (Jul 2026); ACN Newswire (2015, 2018).
-
Modern Dental Group Ltd, FY2025 Final Results (26 Mar 2026) and profit alert (Mar 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Background (where disclosed) |
|---|---|---|---|
Kwok Ying Shing (郭英成) | Chairman, Executive Director | — | Founder and chairman of Kaisa Group; personal holding of 310,020,000 pre-consolidation shares (6.15%) at 30 Jun 2025 |
Luo Jun | Co-Vice Chairman and Chief Executive Officer, Executive Director | Per etnet listing | — |
Luo Tingting | Vice Chairman, Executive Director | A Vice Chairperson appointment was announced late Sep 2025 (TipRanks); etnet lists Ms Luo as Vice Chairman | — |
Xie Binhong | Executive Director | — | — |
Ye Haoda | Executive Director | — | — |
Yang Feng (楊峰) | Executive Director | Appointed July 2026 (announcement 13 Jul 2026); 3-year service contract | Aged 52; president of Qinghai Pharmaceutical, which he joined in 2021; responsible for its overall operation; director's emolument HK$100,000 before tax |
Dr Liu Yanwen | Independent Non-executive Director; Chairman of Audit Committee | — | — |
Dr Lyu Aiping | INED; Audit Committee member | — | — |
Ms Li Zhiying (formerly Li Yonglan) | INED; Audit Committee member | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Kaisa Group Holdings Ltd. (1638.HK) | 2,167,600,491 | 42.99 |
Huang Xiao Gang | 472,470,256 | 9.37 |
Kwok Ying Shing | 310,020,000 | 6.15 |
ABG II-RYD Limited | 270,300,000 | 5.36 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Listing | Positioning vs. company | Revenue (latest, where verified) |
|---|---|---|---|---|
Dental prosthetics | Modern Dental Group | HKEX 3600 | Global leader in custom prosthetics; far larger, profitable | FY2025 revenue HK$3,736.5 million (+11.1%) |
Dental prosthetics (PRC labs) | Regional Chinese dental labs (fragmented) | Mostly private | Price competition under VBP | — |
Dental implants (PRC domestic) | Domestic implant makers participating in national VBP (e.g. Weigao-affiliated, Zhengzhou-based and other domestic brands) | Various | — | — |
Dental implants (global) | Straumann, Nobel Biocare (Envista), Dentsply Sirona, Osstem | SIX / NYSE / NASDAQ / KRX | Premium global brands; dominant share in China pre-VBP | — |
Clear aligners | Align Technology (Invisalign); Angelalign (HKEX 6699); Smartee | NASDAQ / HKEX / private | Mega YiQi is a niche entrant | — |
Narcotics / anaesthetics (PRC) | Yichang Humanwell (subsidiary of Humanwell Healthcare, 600079.SS) | SSE | Widely regarded as China's leading narcotic analgesic producer | — |
Anaesthetics / CNS (PRC) | Jiangsu Nhwa Pharmaceutical | SZSE 002262 | CNS and anaesthesia drugs, including controlled substances | — |
Anaesthetics (PRC) | Jiangsu Hengrui Pharmaceuticals | SSE 600276 | Broad pharma with anaesthesia franchise (e.g. remimazolam) | — |
Anaesthetics (PRC) | Sichuan Haisco Pharmaceutical | SZSE 002653 | Anaesthesia and analgesia (e.g. ciprofol) | — |
Narcotic APIs (PRC) | Other state-designated narcotic API bases (e.g. Northeast Pharmaceutical, Tianjin-based producers) | Various | Licensed oligopoly | — |
Sports rehabilitation (Shenzhen) | Hospital rehab departments; private rehab chains | Mostly private | Hejia is a single clinic | — |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Company FY2025 (legacy) | Company H1 2026 (restated) | Modern Dental FY2025 |
|---|---|---|---|
Revenue | HK$139.1 million | HK$284.6 million (half-year) | HK$3,736.5 million |
Revenue growth | -25.0% | -15.8% | +11.1% |
Gross margin | 36.4% | 37.9% | — |
Net margin | -33.6% | -21.1% (owners) | ≈16% (net profit ≈HK$0.6 billion per profit alert) |
R&D intensity | 12.2% | 9.6% | — |
Recent Developments
--



